Shock! Biotech raises money
Monday, 30 March, 2009
Melbourne stem cell company Mesoblast has raised $10.81 million through a private placement to existing as well as new and institutional investors.
The money will be used to further the company’s clinical trial programs, including its bone and cartilage regenerative products.
Mesoblast said the placement of 15.02 million shares was oversubscribed.
The money will come as a boost to the company’s cash reserves, which were $9.6 million as at December 31, 2008.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...